LEXICON PHARMACEUTICALS, INC. Investments, Fair Value Disclosure
LEXICON PHARMACEUTICALS, INC. (LXRX) had Investments, Fair Value Disclosure of $218.43 million as of 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Notes › Fair Value Disclosures
us-gaap:InvestmentsFairValueDisclosure · last filed 2023-11-08
- 2023-09-30: Investments, Fair Value Disclosure $218.43M.
- 2023-06-30: Investments, Fair Value Disclosure $256.74M.
- 2023-03-31: Investments, Fair Value Disclosure $105.94M.
- 2022-12-31: Investments, Fair Value Disclosure $138.36M.
| Period end | Investments, Fair Value Disclosure |
|---|---|
| 2023-09-30 | $218.43M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $256.74M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $105.94M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $138.36M 10-Q · filed 2023-11-08 |
| 2022-09-30 | $136.20M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $61.97M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $86.50M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $86.74M 10-K · filed 2023-03-03 |
| 2021-09-30 | $120.92M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $118.50M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $141.36M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $152.28M 10-K · filed 2022-03-10 |
| 2020-09-30 | $111.45M 10-Q · filed 2020-10-30 |
| 2020-06-30 | $201.87M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $249.14M 10-Q · filed 2020-04-27 |
| 2019-12-31 | $271.66M 10-K · filed 2021-03-12 |
| 2019-09-30 | $296.30M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $105.98M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $133.15M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $160.05M 10-K · filed 2020-03-12 |
| 2018-09-30 | $187.30M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $209.69M 10-Q · filed 2018-07-30 |
| 2018-03-31 | $262.27M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $310.79M 10-K · filed 2019-03-15 |
| 2017-09-30 | $196.82M 10-Q · filed 2017-11-08 |
| 2016-12-31 | $346.50M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |